Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Specialists LLC

Neither a doctor nor a teaching hospital

Research payments

$1,642,675

816 payments

Through program year 2025, Clinical Research Specialists LLC is reported as receiving $1,642,675 in research payments, across 816 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $332,645 242
2024 Research $201,672 167
2023 Research $273,088 33
2022 Research $494,925 123
2021 Research $235,514 231
2020 Research $28,967 8
2019 Research $75,863 12

Breakdown

Who paid Research payments · program years 2019–2025
  1. Insmed, Inc. $517,366 505 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $456,352 90 payments
  3. GlaxoSmithKline, LLC. $358,456 49 payments
  4. Roche Products Limited $130,916 16 payments
  5. Regeneron Pharmaceuticals, Inc. $50,492 66 payments
  6. Genzyme Corporation $47,196 10 payments
  7. Boehringer Ingelheim International GmbH $32,213 63 payments
  8. Cipla USA Inc. $26,590 3 payments
  9. Janssen Research & Development, LLC $13,750 4 payments
  10. United Therapeutics Corporation $9,344 10 payments
Studies the money was for Research payments · program years 2019–2025
  1. A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $288,010 43 payments
  2. PDE4 Phase III trial in IPF patients $177,827 20 payments
  3. A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact $169,415 102 payments
  4. Trial to Evaluate the Efficacy and Safety of PRM 151 in Patients With Idiopathic Pulmonary Fibrosis $130,916 16 payments
  5. ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) $109,220 116 payments
  6. An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) $108,819 54 payments
  7. A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) $95,426 77 payments
  8. ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) $89,867 94 payments
  9. A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) $61,942 40 payments
  10. A Phase IV, 12 Week, Randomised, Double Blind Study to Compare Single $52,946 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record